Frontier Biotechnologies Inc
SSE:688221
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Frontier Biotechnologies Inc
SSE:688221
|
CN |
|
Queensland Pacific Metals Ltd
ASX:QPM
|
AU |
|
Amte Power PLC
LSE:AMTE
|
UK |
|
I
|
Instal Krakow SA
WSE:INK
|
PL |
|
T
|
Tiande Chemical Holdings Ltd
HKEX:609
|
HK |
Frontier Biotechnologies Inc
Frontier Biotechnologies, Inc. engages in the research and development, production, and sale of medicines. The company is headquartered in Nanjing, Jiangsu and currently employs 495 full-time employees. The company went IPO on 2020-10-28. The firm's products include Aikening and Combination regiment of Albuvirtide (ABT) + 3BNC117 which is during clinical stage for treatment of human immunodeficiency virus (HIV). Its clinical-stage products also include transdermal analgesic patch AB001 for treating muscle, skeleton and joint pain. The firm conducts its businesses within the China market and to overseas markets.
Frontier Biotechnologies, Inc. engages in the research and development, production, and sale of medicines. The company is headquartered in Nanjing, Jiangsu and currently employs 495 full-time employees. The company went IPO on 2020-10-28. The firm's products include Aikening and Combination regiment of Albuvirtide (ABT) + 3BNC117 which is during clinical stage for treatment of human immunodeficiency virus (HIV). Its clinical-stage products also include transdermal analgesic patch AB001 for treating muscle, skeleton and joint pain. The firm conducts its businesses within the China market and to overseas markets.
